Budesonide controlled release - Pharmalink

Drug Profile

Budesonide controlled release - Pharmalink

Alternative Names: Nefecon; PL-56

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Uppsala University
  • Developer Pharmalink AB
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Corticosteroids; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II IgA nephropathy

Most Recent Events

  • 29 Nov 2016 Budesonide controlled release - Pharmalink receives Orphan Drug status for IgA nephropathy in European Union
  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2015 Pharmalink plans a phase III trial for IgA nephropathy in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top